Ministry of Health and Welfare Provides Additional Clinical Support for Two COVID-19 Therapeutics and Two Vaccines
Increased to a total of 10 types, including 5 treatments and 5 vaccines
[Asia Economy Reporter Kim Ji-hee] The government is expanding clinical support for the development of treatments and vaccines for the novel coronavirus infection (COVID-19).
The Central Disaster and Safety Countermeasures Headquarters of the Ministry of Health and Welfare announced on the 26th that, as a result of the third public selection for clinical support of COVID-19 treatments and vaccines, two treatments and two vaccines were selected for clinical support. Accordingly, in addition to the six types previously approved for support in two rounds, the total number of treatments and vaccines currently receiving clinical support from the Ministry of Health and Welfare has reached 10 (five treatments and five vaccines).
In this third project call, 10 projects applied, including eight treatments and two vaccines, and four projects were finally selected on the 22nd. Celltrion's antibody treatment will receive support for phase 3 clinical trials, and Daewoong Pharmaceutical's drug repurposing treatment will receive support for phases 2 and 3. Vaccines from Cellid and UbioLogics will receive support for phases 1 and 2.
To support the development of treatments and vaccines, the government expanded the 2021 budget to 138.8 billion KRW. Including this third public call, the government is providing a total of 36.4 billion KRW for five vaccine projects and 84.4 billion KRW for five treatment projects in clinical trials for COVID-19 treatments and vaccines. The vaccines include Genexine, SK Bioscience, GeneOne Life Science, Cellid, and UbioLogics, while the treatments include Celltrion (two projects), Green Cross, and Daewoong Pharmaceutical (two projects).
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
In addition to the budget, various supports for rapid development are ongoing. Since September last year, the 'National Infectious Disease Clinical Trial Center' has been operating to support rapid recruitment of subjects and joint IRB operations, and a consortium of base hospitals and infectious disease specialized hospitals has been formed to actively facilitate clinical trials. Furthermore, the 'Clinical Trial Support Task Force,' composed of relevant ministries and private experts, is operating to improve difficulties faced by companies.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
